Companies Advised To ‘Re-Think’ SPC & Regulatory Strategies For ‘Loose’ Combination Products
Executive Summary
A key problem with obtaining supplementary protection certificates for combination drug therapies, particularly for “add-on” therapies where patients have access to the remaining active components, was highlighted in a UK court case judgement, the principle of which is expected to be followed in Europe.